Medical Laboratories Stocks Under Scanner -- Great Basin Scientific, Biocept, Quintiles IMS, and OpGen

Wednesday, March 8, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 8, 2017 /PRNewswire/ --

For today, has lined up four equities in the Medical Laboratories

and Research space: Great Basin Scientific Inc. (NASDAQ: GBSN), Biocept Inc. (NASDAQ: BIOC), Quintiles IMS Holdings Inc. (NYSE: Q), and OpGen Inc. (NASDAQ: OPGN). These companies operate in the Healthcare sector, which was still mostly underwater on
Tuesday, March 07th, 2017, with the NYSE Health Care Index falling nearly 0.5%, while shares of health care companies in the S&P 500 were down almost 0.4% as a group. You can access our complimentary research reports on these stocks now at:

Great Basin Scientific  

Shares in Salt Lake City, Utah headquartered Great Basin Scientific Inc. saw a drop of 12.39% on Tuesday. The stock recorded a trading volume of 105.42 million shares. Shares of the Company, which develops and commercializes molecular diagnostic systems that are designed to test hospital-acquired infections, are trading 16.38% above their 50-day moving average.

On February 15th, 2017, Great Basin Scientific announced the Journal of Clinical Microbiology published results of a multicenter study that demonstrated the effectiveness of its Staph ID/R Blood Culture Panel in rapidly identifying several species of Staphylococci and in accurately detecting the mecA gene directly from a positive blood culture. The results of the study, which was conducted across three clinical sites, demonstrated the performance and efficacy of the Staph ID/R Blood Culture Panel compared to conventional methods, and concluded that the Company's panel provided decreased time to results at a lower price, helping physicians diagnose and deliver a timely, accurate, and cost-effective course of treatment. Visit us today and download your complete report on GBSN for free at:


San Diego, California headquartered Biocept Inc.'s stock declined 5.04%, closing the day at $2.26 with a total trading volume of 1.69 million shares. The Company's shares have surged 47.71% in the past month, 179.01% in the previous three months, and 191.61% since the start of this year. The stock is trading 38.42% and 131.74% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Biocept, which develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample, have an RSI of 60.97.

On March 07th, 2017, Biocept reported that it accessioned 1,101 billable samples in Q4 2016, a 78% increase from 618 billable samples accessioned during Q4 2015. Revenues for Q4 2016 increased to $1.3 million from $218,000 for Q4 2015. The Company's net loss for Q4 2016 was $4.2 million, or $0.27 per share, compared to a net loss for Q4 2015 of $4.6 million, or $0.73 per share. Biocept reported cash and cash equivalents of $4.6 million as of December 31st, 2016, compared to $8.8 million as of December 31st, 2015. The complimentary research report on BIOC can be accessed at:

Quintiles IMS  

On Tuesday, shares in Durham, North Carolina headquartered Quintiles IMS Holdings Inc. recorded a trading volume of 1.34 million shares. The stock ended the day 0.54% lower at $77.48. The Company's shares have advanced 4.66% in the previous three months and 1.88% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.37% and 3.50%, respectively. Furthermore, shares of Quintiles IMS Holdings, which provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and Asia/Pacific, have an RSI of 48.88.

On February 17th, 2017, research firm Wells Fargo upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.

As per a SEC filing dated February 28th, 2017, Quintiles IMS Inc., a wholly-owned subsidiary of Quintiles IMS Holdings, completed the issuance and sale of €1.43 billion in gross proceeds of the Issuer's 3.25% Senior Notes due 2025. The Notes are unsecured obligations of the Issuer, will mature on March 15th, 2025, and will bear interest at the rate of 3.25% per year, with interest payable semi-annually on March 15th and September 15th of each year, beginning on September 15th, 2017. Register for free on and download the PDF research report on Q at:


Gaithersburg, Maryland headquartered OpGen Inc.'s stock rose 3.00%, finishing yesterday's session at $1.03 with a total trading volume of 361,735 shares. The Company's shares are trading below their 50-day moving average by 10.25%. Shares of the Company, which engages in developing and deploying precision medicine tools to combat infectious disease in global healthcare settings, have an RSI of 43.04.

On March 14th, 2017, OpGen announced preliminary data demonstrating the ability to rapidly and accurately predict bacterial antibiotic susceptibility using resistance gene profiles. These preliminary results support OpGen's ongoing genomic and bioinformatics efforts to complete development and commercialization of rapid and highly accurate molecular antibiotic susceptibility determination products for hospital- and network-wide infection prevention and patient management. Get free access to your research report on OPGN at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store